Adjuvant Chemotherapy of Stage I Non-small Cell Lung Cancer in North America
Journal of Thoracic OncologyPublished 1 July 2007Open access
David R. Gandara, Heather A. Wakelee, Royce Calhoun, David M. Jablons
Citations9
SJR quartileQ1
SJR score7.95
SNIP4.49
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
It is shown that subset analysis has uniformly shown the greatest efficacy for patients with stage II and III disease and the least benefit for patient with stage I disease.
Abstract
The utility of adjuvant chemotherapy after surgical resection for early-stage non-small cell lung cancer (NSCLC) is now well established. Although a number of randomized clinical trials have demonstrated the efficacy of platinum-based chemotherapy in the overall population treated, subset analysis, excepting Japanese studies, has uniformly shown the greatest efficacy for patients with stage II and III disease and the least benefit for patient with stage I disease. We review data regarding adjuvant therapy of stage I NSCLC from clinical trials performed in North America and Europe. Pertinent trials from Japan are discussed elsewhere in this issue.
Keywords
Medicine
New England Journal of MedicineErlotinib in Previously Treated Non–Small-Cell Lung Cancer
5,428 Citations2005Frances A. Shepherd, José Rodrigues Pereira +17 more
Elotinib can prolong survival in patients with non-small-cell lung cancer after first-line or second-line chemotherapy, and five percent of patients discontinued erlot inib because of toxic effects.
Journal of Clinical OncologyMulti-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
2,887 Citations2003Masahiro Fukuoka, Seiji Yano +18 more
Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in patients with pretreated advanced non-small-cell lung cancer.
BMJChemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials
2,850 Citations1995Non-small Cell Lung Cancer Collaborative Group
The results of this meta-analysis suggest that chemotherapy may have a role in treating non-small cell lung cancer, and reached conventional levels of significance when used with radical radiotherapy and with supportive care.
Critical Reviews in Oncology/HematologyEpidermal growth factor-related peptides and their receptors in human malignancies
2,687 Citations1995David S. Salomon, Ralf Brandt +2 more
JAMAEfficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer
2,526 Citations2003Mark G. Kris, Ronald B. Natale +14 more
Gefitinib, a well-tolerated oral EGFR-tyrosine kinase inhibitor, improved disease-related symptoms and induced radiographic tumor regressions in patients with NSCLC persisting after chemotherapy.
New England Journal of MedicineCisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non–Small-Cell Lung Cancer
2,336 Citations2004R. Arriagada
Cisplatin-based adjuvant chemotherapy improves survival among patients with completely resected non-small-cell lung cancer and had a significantly higher survival rate than those assigned to observation.
New England Journal of MedicineVinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer
1,815 Citations2005Timothy Winton, Robert B. Livingston +19 more
Adjuvant vinorelbine plus cisplatin has an acceptable level of toxicity and prolongs disease-free and overall survival among patients with completely resected early-stage non-small-cell lung cancer.
JNCI Journal of the National Cancer InstituteRandomized Study of Adjuvant Chemotherapy for Completely Resected Stage I, II, or IIIA Non-Small-Cell Lung Cancer
599 Citations2003Giorgio V. Scagliotti
This randomized trial failed to prospectively confirm a statistically significant role for adjuvant chemotherapy in completely resected NSCLC and given the poor compliance with the MVP regimen used in this study, future studies should explore more effective treatments.
New England Journal of MedicineA Randomized Trial of Postoperative Adjuvant Therapy in Patients with Completely Resected Stage II or IIIa Non–Small-Cell Lung Cancer
450 Citations2000Steven M. Keller, Sudeshna Adak +7 more
As compared with radiotherapy alone, adjuvant radiotherapy and chemotherapy with cisplatin and etoposide does not decrease the risk of intrathoracic recurrence or prolong survival in patients with completely resected stage II or IIIa non-small-cell lung cancer.
European Journal of Cardio-Thoracic SurgeryChemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial1
389 Citations2004David Waller, Michael Peake +7 more
This trial has failed to observe a survival benefit with adjuvant chemotherapy following complete resection of stage I-III NSCLC, but the hazard ratio and 95% confidence intervals are consistent with the previously reported meta-analysis and two large recently reported trials, which suggest a small survival Benefit with cisplatin-based chemotherapy.
Journal of Clinical OncologyRandomized Clinical Trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB Non-Small Cell Lung Cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633
367 Citations2004Gary M. Strauss, James E. Herndon +7 more
Adjuvant chemotherapy significantly reduces all-cause and lung cancer mortality in stage IB NSCLC and is the first randomized trial to demonstrate significantly improved survival for a carboplatin-based adjuvant chemotherapy regimen in a uniform population withNSCLC.
Journal of Clinical OncologyRandomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599
360 Citations2005Alan B. Sandler, R Gray +5 more
This randomized phase II trial of PC +/- bevacizumab (A) suggested improved activity for the combination of PCA when compared to PC alone, and multivariate analysis suggested squamous cell histology to be a significant risk factor.
Seminars in OncologyOverview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia
304 Citations2002CL Arteaga
Early clinical studies already suggest that both of these approaches, either alone or in combination with standard anticancer therapies, alter the natural history of EGFR-expressing cancers with little toxicity to the tumor-bearing host.
Journal of Clinical OncologyAdjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): Update of Cancer and Leukemia Group B (CALGB) protocol 9633
178 Citations2006Gary M. Strauss, James E. Herndon +8 more
This updated but "preliminary" analysis no longer shows a significant OS advantage for adjuvant chemotherapy in stage IB NSCLC, however, the re-designed study does not have adequate power to detect small differences in OS that may be clinically significant.
Journal of Clinical OncologyANITA: Phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage I-III) non-small-cell lung cancer (NSCLC) patients (pts): Final results after 70-month median follow-up. On behalf of the Adjuvant Navelbine International Trialist Association
161 Citations2005J.-Y. Douillard, R. Rosell +4 more
The randomized, prospective phase III trial ANITA compared the effectiveness of adjuvant NP versus OBS in early NSCLC as well as stratified by center, stage and histology.
Journal of Clinical OncologyLung Adjuvant Cisplatin Evaluation (LACE): A pooled analysis of five randomized clinical trials including 4,584 patients
157 Citations2006Jean‐Pierre Pignon, Hélène Tribodet +5 more
It is suggested that platinum-based adjuvant chemotherapy may not benefit stage I-A patients, and adjuvant cisplatin-based chemotherapy improves survival in patients with NSCLC.